Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE
Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias
Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias
View: Text | PDF
Research Article Inflammation

NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE

  • Text
  • PDF
Abstract

IL-33, a nuclear alarmin released during cell death, exerts context-specific effects on adaptive and innate immune cells, eliciting potent inflammatory responses. We screened blood, skin, and kidney tissues from patients with systemic lupus erythematosus (SLE), a systemic autoimmune disease driven by unabated type I IFN production, and found increased amounts of extracellular IL-33 complexed with neutrophil extracellular traps (NETs), correlating with severe, active disease. Using a combination of molecular, imaging, and proteomic approaches, we show that SLE neutrophils, activated by disease immunocomplexes, release IL-33–decorated NETs that stimulate robust IFN-α synthesis by plasmacytoid DCs in a manner dependent on the IL-33 receptor ST2L. IL33-silenced neutrophil-like cells cultured under lupus-inducing conditions generated NETs with diminished interferogenic effect. Importantly, NETs derived from patients with SLE are enriched in mature bioactive isoforms of IL-33 processed by the neutrophil proteases elastase and cathepsin G. Pharmacological inhibition of these proteases neutralized IL-33–dependent IFN-α production elicited by NETs. We believe these data demonstrate a novel role for cleaved IL-33 alarmin decorating NETs in human SLE, linking neutrophil activation, type I IFN production, and end-organ inflammation, with skin pathology mirroring that observed in the kidneys.

Authors

Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias

×

Figure 4

SLE NETs induced a robust IFN-α response by pDCs in an ST2L-dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
SLE NETs induced a robust IFN-α response by pDCs in an ST2L-dependent ma...
(A) Real-time PCR (left panel) and ELISA (right panel) were performed to determine mRNA and protein expression or secretion of IFN-α, respectively, by healthy pDCs treated overnight with IC-induced SLE NET-containing supernatants (IC NETs) (25% v/v). The contribution of the IL-33/ST2L axis on IFN-α response was assessed by pretreating pDCs with an antibody against ST2L (a-ST2L, 3 μg/mL). FcR blocking reagent was used to avoid any IC-carry over effect or non-specific a-ST2L binding. Each dot represents a different pDC donor (n = 12) and bar plots show the mean ± SEM expression. *P < 0.05; ***P < 0.001 (2-tailed, repeated measures ANOVA with Holm-Sidak correction). (B) Real-time PCR for IRF7 mRNA expression in pDCs (n = 12 healthy donors) stimulated with IC NETs (25% v/v), with or without pre-treatment with FcR blocking agent and a-ST2L, as described for A. Quantification was performed using the 2-ΔΔCT method, where ΔCt = IRF7 Ct minus GAPDH Ct. **P < 0.01 (2-tailed, repeated measures ANOVA with Holm-Sidak correction). (C) Intracellular p-IRF7 staining was performed 4 hours after stimulation of purified pDCs with IC NETs (25% v/v), with or without pretreatment with FcR blocking agent and a-ST2L, as described for A. Each dot (open circle, full circle, triangle) corresponds to the kinetics of p-IRF7 in 9 independent donors, and bar plots show the mean ± SEM expression. *P < 0.05 (2-tailed, repeated measures ANOVA with Holm-Sidak correction). Right panel illustrates a representative flow cytometry histogram of intracellular p-IRF7 levels in pDCs treated as described for A. MFI, mean fluorescence intensity.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts